HMP Global sets 2026 Clinical Pathways Congress agenda around oncology, AI and value-based care

HMP Global released the full agenda for its 2026 Clinical Pathways Congress, set for Nov. 10-11 at the Four Seasons Hotel Boston. The 10th annual meeting will focus on pathway economics, AI, real-world evidence, reimbursement and the patient voice as oncology care models face growing financial pressure.

Why it matters: - The Clinical Pathways Congress is a key meeting for oncology leaders shaping how cancer care is designed, paid for and delivered. - The 2026 agenda puts practical execution ahead of theory at a moment when pathway governance, reimbursement pressure and AI adoption are becoming more intertwined. - The meeting is the official event of the Journal of Clinical Pathways, giving the program added reach across providers, payers, pharmacy leaders, policymakers and life sciences partners.

What happened: - HMP Global released the full 2026 agenda for the Clinical Pathways Congress on June 23, 2026. - The congress will take place Nov. 10-11, 2026, at the Four Seasons Hotel Boston in Boston, Massachusetts. - The 2026 event marks the congress's 10th year. - The congress is built around clinical pathway design, governance and value-based cancer care.

The details: - The program centers on four areas: pathway economics and financial sustainability; data, AI and real-world evidence; policy, regulation and reimbursement; and the patient voice in pathway development. - Sessions are organized around the Journal of Clinical Pathways framework of Business, Outcome Measurements, Infrastructure & Innovation, and Consistency & Ethics. - Scheduled sessions include topics on building pathways that drive value, aligning innovation with financial sustainability, integrating AI and real-world evidence, navigating regulation and reimbursement, provider-pharma collaboration, shared savings and contracting, and embedding patient perspectives into pathway design. - The agenda also includes CP NEXT, a live session tied to the congress's year-round extension for discussion between annual meetings. - Confirmed faculty includes leaders from provider organizations, payer and managed care groups, pharmacy, patient advocacy, technology and life sciences. - Confirmed speakers include Gordon Kuntz of Kuntz Consulting; Alan J. Balch of Patient Advocate Foundation; Tori Handy of The US Oncology Network/McKesson; Deirdre Saulet of Jasper Health; Olaf Lodbrok of Elsevier; Jorge Garcia of Baptist Health South Florida; Lalan Wilfong of Navista; Carole Tremonti of ConcertAI; Andrew Norden of OncoHealth; Edward Arrowsmith of Tennessee Oncology; Alti Rahman of American Oncology Network; Linda Bosserman of City of Hope; David Jackman of Dana-Farber Cancer Institute; Mishellene McKinney of Kaiser Permanente; Adam Colborn of the Academy of Managed Care Pharmacy; John Carey of Johnson & Johnson; Clayton Wright of Takeda Oncology; and Ira Klein of Tempus AI. - Additional faculty will be announced as the program is finalized. - The 2026 steering committee includes Alan J. Balch, Aimee Ginsburg Chesnick and Deirdre Saulet. - The full agenda is available here. - Discounted registration is available through Sept. 4, 2026. - Event information is posted at the congress website and registration rates.

Between the lines: - The agenda shift reflects a field moving from proving pathways matter to making them work inside complex care, payment and technology systems. - The strong focus on AI and real-world evidence suggests oncology pathway leaders are looking for tools that can support more dynamic decision-making without losing clinical consistency. - The emphasis on patient voice and equity signals that pathway design is being framed as both a clinical and a care-delivery issue, not just a cost-control exercise. - Gordon Kuntz said the 2026 program was built around the day-to-day questions leaders face on funding, governance, AI, real-world evidence and patient-centered care.

What's next: - HMP Global will add more faculty as the program is finalized. - Oncology leaders, payers, pharmacists and policy stakeholders have until Sept. 4 to secure discounted registration. - The November meeting will test how far the field has moved from pathway strategy to pathway execution.

The bottom line: - Clinical pathways are moving deeper into the mechanics of value-based cancer care, and HMP Global is making that the center of its 2026 oncology meeting.